NomineSalute - farmaceutica - biotech
Inside Information / Other news releases
06/11/2026 17:45
AMFPubblicazione immediata
Dallas (United States) & Lyon (France), November 6, 2026 – 5:45 pm CET – SMAIO (Software, Machines and Adaptative Implants in Orthopaedics – Euronext Growth Paris, ISIN code: FR0014005I80 / Ticker: ALSMA, PEA-PME eligible), a French-American company specialized in complex spine surgery and…
P R E S S R E L E A S E
S M A I O h a s r e a p p o i n t e d D r Te n n e r
G u i l l a u m e t o i t s s c i e n t i f i c a d v i s o r y b o a r d i n t h e U n i t e d S t a t e s
Dallas (United States) & Lyon (France), November 6, 2026 – 5:45 pm CET – SMAIO (Software, Machines and Adaptative Implants in Orthopaedics – Euronext Growth Paris, ISIN code: FR0014005I80 / Ticker: ALSMA, PEA-PME eligible), a French-American company specialized in complex spine surgery and offering an integrated pre-, intra- and postoperative solution based on 3D planning software, adaptive implants and related services, today announces the renewal of the term of office of Dr Tenner Guillaume, Orthopaedic Surgeon at Gillette Children's Hospital (St. Paul, Minnesota), on its scientific advisory board in the United States.
Appointed to the Scientific Advisory Board on October 29, 2025 for an initial term of 12 months, Dr Tenner Guillaume has played an active role in the work of the expert group, which currently comprises five renowned North American surgeons.
Today, the Company is delighted to announce the renewal of his term of office for a further 12 months, under the same terms as his previous mandate.
The terms of remuneration of Dr Tenner Guillaume as a member of the scientific advisory board, primarily in the form of warrants, are set out in the appendix to this press release.
About SMAIO
A precursor in the use of clinical data and imaging of the spine, SMAIO designs global solutions for spine surgery specialists. The Company has recognized expertise thanks to its big data database, which has become a global reference with more than 100,000 patient cases documented. SMAIO offers spine surgeons a comprehensive platform, i-Kontrol, incorporating planning, implantable devices and related services, enabling them to treat spinal pathologies in a safe, effective and lasting way. The open platform deployed by the Company in the United States, KEOPS-4ME, is designed to offer a personalized and data-driven approach for complex spine surgeries, enabling SMAIO to enter into commercial partnerships with major US surgical companies and to provide their surgeon customers with patientspecific implants. Based in Dallas (United States) and Lyon (France), SMAIO benefits from the skill and expertise of more than 50 highly specialized employees.
For further information, please visit: www.smaio.com
Contacts SMAIO
SMAIO
Philippe Roussouly
Chief Executive Officer
Renaut Fritsch